跳至主要内容
临床试验/NCT04236687
NCT04236687Unknown不适用

Prospective, Controlled Investigation of Prostate Artery Embolization Compared to Holmium Laser Enucleation of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia

Germans Trias i Pujol Hospital2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2020年2月1日最近更新:
适应症

试验速览

阶段
不适用
入组人数
100
试验地点
2
主要终点
Improvement of symptoms assessed by International Prostate Symptom Score (IPSS)

研究概览

简要总结

The purpose of this study is to evaluate improvement of symptoms from benign prostatic hyperplasia (BPH) as assessed by the International Prostate Symptom Score (IPSS) for prostate artery embolization (PAE) with microspheres (Embozene™, 400µm) compared to conventional Holmium laser enucleation of the prostate (HoLEP).

详细描述

This is a prospective randomized controlled study that collects data of patients with benign prostatic hyperplasia that are treated with prostatic artery embolization (PAE) or with Holmium laser enucleation of the prostate (HoLEP). For PAE a catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate. The injected microspheres will slow the blood flow to the prostate. For HoLEP a Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra. Clinical follow-up include clinical visit after 1, 6 and 12 months. Acute as well as long term complications will be recorded. The patients fill in the questionnaires for urologic disease. Urodynamic examination will record functional outcome.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Patients evaluated in the urology department and candidates to surgical treatment
  • Age > 45 years
  • IPSS ≥ 10
  • Maximum urinary flow < 12 milliliters (mL)/second (s)
  • Post-void residual urinary volume < 300mL
  • Prostatic volume between 20mL and 250mL assessed by ultrasound
  • Signed informed consent

排除标准

  • PSA > 10 (if not negative prostate biopsy)
  • Life expectancy below 1 year
  • Renal insufficiency defined as Glomerular Filtration Rate < 30 ml/min/1,73m2
  • Known severe reactions to iodine-based contrast or gadolinium-based contrast
  • CT examination reveals no access to the prostate arteries.

结局指标

主要结局

Improvement of symptoms assessed by International Prostate Symptom Score (IPSS)

时间窗: Baseline to 6 months after procedure

Change in prostatic symptoms using the International Prostate Symptom Score (IPSS). IPSS score goes from 0 to 35. Higher values mean worse outcome (prostate symptons)

次要结局

  • Maximum urinary flow(Baseline to 6 months after procedure)
  • Post-void residual urinary volume(Baseline to 6 months after procedure)
  • Prostate specific antigen (PSA)(Baseline to 6 months after procedure)
  • Procedure related adverse events(Baseline to 6 months after procedure)
  • Procedure related effects on sexual function(Baseline to 6 months after procedure)
  • Procedure related effects on urinary continence(Baseline to 6 months after procedure)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验